| scholarly article | Q13442814 |
| P50 | author | Ernesto German Cardona MuÑoz | Q43145202 |
| Mónica Vázquez-Del Mercado | Q51803035 | ||
| Benjamin Trujillo-Hernandez | Q60317601 | ||
| Norma Alejandra Rodriguez Jimenez | Q88548326 | ||
| P2093 | author name string | Laura Gonzalez-Lopez | |
| Esther Guadalupe Corona-Sanchez | |||
| Mario Salazar-Paramo | |||
| Alberto Daniel Rocha-Muñoz | |||
| Jorge I Gamez-Nava | |||
| Adolfo Cota-Sanchez | |||
| Carlos E Garcia-Gonzalez | |||
| Erika Anita Aguilar-Chavez | |||
| Eva Olivas-Flores | |||
| Evangelina Varon-Villalpando | |||
| Jose Clemente Vasquez-Jimenez | |||
| Karina Patricia Ayala-Lopez | |||
| P2860 | cites work | Metabolic syndrome in rheumatoid arthritis | Q26822038 |
| Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis | Q33563669 | ||
| Cachexia | Q34061258 | ||
| Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease | Q34459100 | ||
| Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies | Q34889152 | ||
| Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis | Q35547305 | ||
| Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis | Q35954510 | ||
| Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy | Q36151574 | ||
| Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis | Q36204149 | ||
| Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence | Q36422727 | ||
| Atherogenic lipid profiles and its management in patients with rheumatoid arthritis | Q36596894 | ||
| Sustained changes in lipid profile and macrophage migration inhibitory factor levels after anti-tumour necrosis factor therapy in rheumatoid arthritis | Q37245188 | ||
| A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis | Q37728928 | ||
| Glucocorticoids and cardiovascular risk factors | Q37874810 | ||
| Update of the Mexican College of Rheumatology guidelines for the pharmacologic treatment of rheumatoid arthritis | Q38170855 | ||
| Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. | Q39405773 | ||
| Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study | Q39863525 | ||
| Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis | Q42498499 | ||
| The APOM polymorphism as a novel risk factor for dyslipidaemia in rheumatoid arthritis: a possible shared link between disease susceptibility and dyslipidaemia. | Q42678550 | ||
| Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis | Q43315904 | ||
| Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. | Q43426783 | ||
| Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice | Q43865549 | ||
| High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. | Q46361815 | ||
| Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients | Q46810525 | ||
| The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor | Q46846288 | ||
| Preclinical carotid atherosclerosis in patients with rheumatoid arthritis | Q46954458 | ||
| Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis | Q46987065 | ||
| Atherogenic lipid profiles in rheumatoid arthritis. | Q51491632 | ||
| Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. | Q51695204 | ||
| Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. | Q53249650 | ||
| TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. | Q53511273 | ||
| Tumor necrosis factor-alpha -1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis. | Q54524130 | ||
| NFKB1-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis | Q57307062 | ||
| TNFA −308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis | Q57307074 | ||
| Anti-tumour necrosis factor agents and lipid profile: a class effect? | Q57830844 | ||
| Dyslipoproteinemia in the course of active rheumatoid arthritis | Q67478509 | ||
| Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease | Q79354392 | ||
| Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis | Q79610823 | ||
| Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab | Q79996729 | ||
| Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritis | Q80657531 | ||
| Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis | Q81235634 | ||
| Cardiovascular death in rheumatoid arthritis: a population-based study | Q81484761 | ||
| Etanercept increases adiponectin level in woman with rheumatoid arthritis | Q81691961 | ||
| The safety and efficacy of etanercept on cardiac functions and lipid profile in patients with active rheumatoid arthritis | Q82414676 | ||
| Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy | Q82734935 | ||
| Comments on the original article by Soubrier et al. "Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis" | Q82976143 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| methotrexate | Q422232 | ||
| TNF | Q18032037 | ||
| P304 | page(s) | 510305 | |
| P577 | publication date | 2014-08-27 | |
| P1433 | published in | BioMed Research International | Q17509958 |
| P1476 | title | Modifications in lipid levels are independent of serum TNF-α in rheumatoid arthritis: results of an observational 24-week cohort study comparing patients receiving etanercept plus methotrexate or methotrexate as monotherapy | |
| P478 | volume | 2014 |
| Q38741861 | Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism |
| Q59135667 | Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate |
| Q46172380 | Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. |
| Q50109832 | The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review |
Search more.